# Differential Gene Expression (DEG) Validation Report

- **Job ID**: `c124c3f7-5d24-4293-b4cc-4787a18b79ea`
- **Execution Date**: 2026-06-07 21:51:15 UTC
- **Workflow Mode**: 58389 total genes processed.

## 1. Input Validation and Normalization Summary
- **Max Expression Value**: 1132887.0
- **Is Integer Counts**: True
- **Is Log Transformed**: False
- **Normalization Applied**: Applied CPM + log2(CPM+1)
- **ID Mapping Success Rate**: 45.08% (26324/58389)

## 2. Differential Expression Summary
- **Total Genes Tested**: 15,519
- **Significant DEGs (FDR < 0.05, |log2FC| >= 1.0)**: 258
  - **Upregulated**: 159
  - **Downregulated**: 99

## 3. Enrichment Analysis (Top 5)
### Gene Ontology Enriched Terms
- **Antigen Processing And Presentation Of Exogenous Peptide Antigen Via MHC Class II (GO:0019886)** (Overlap: 7/26, adj.p=4.6924e-05)
- **Antigen Processing And Presentation Of Peptide Antigen Via MHC Class II (GO:0002495)** (Overlap: 7/28, adj.p=4.6924e-05)
- **Antigen Processing And Presentation Of Exogenous Peptide Antigen (GO:0002478)** (Overlap: 7/31, adj.p=6.7217e-05)
- **Regulation Of Viral Genome Replication (GO:0045069)** (Overlap: 9/67, adj.p=8.7324e-05)
- **Defense Response To Symbiont (GO:0140546)** (Overlap: 12/148, adj.p=1.6291e-04)

### KEGG Pathways Enriched Terms
- **Staphylococcus aureus infection** (Overlap: 11/95, adj.p=8.4270e-06)
- **Allograft rejection** (Overlap: 7/38, adj.p=4.7615e-05)
- **Phagosome** (Overlap: 12/152, adj.p=4.7615e-05)
- **Graft-versus-host disease** (Overlap: 7/42, adj.p=5.0131e-05)
- **Type I diabetes mellitus** (Overlap: 7/43, adj.p=5.0131e-05)

## 4. PubMed Literature Citations
- **PMID 42250070**: *Remote Ischemic Preconditioning Enhances Skin Flap Survival via ZNF667/SDF1-Mediated Endothelial Progenitor Cells Functions for Angiogenesis.* (Tissue engineering and regenerative medicine, 2026)
  - *Abstract*: Flap transplantation plays a vital role in wound reconstruction. However, the mechanisms by which remote ischemic preconditioning (RIPC) may improve flap survival remain incompletely understood. Rats were randomly assigned to three groups: sham, isch...
- **PMID 42232515**: *Multi-omics mendelian randomization integrating GWAS and eQTL data revealed potential drug target for irritable bowel syndrome.* (Frontiers in genetics, 2026)
  - *Abstract*: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder mainly affecting the young and female with limited therapeutic options, necessitating the identification of novel drug targets. This study aimed to identify and prioritize new, gene...
- **PMID 42251442**: *From weeks to hours: rapid whole-genome sequencing reduces diagnostic odyssey in Menke-Hennekam syndrome-a case report.* (Journal of medical case reports, 2026)
  - *Abstract*: Menke-Hennekam syndrome (MKHK) is a rare autosomal dominant disorder caused by mutations in the CREBBP and EP300 genes. The absence of established diagnostic criteria and non-specific clinical manifestations complicate timely diagnosis and management...

## 5. AI pathology Interpretation Summary
### Evidence:
*   **EP300** is significantly upregulated (log2FC=1.19, adj.p=0.0000). EP300, a histone acetyltransferase, is known to be involved in global gene expression regulation and developmental disorders, as evidenced by its mutation in Menke-Hennekam syndrome (PMID: 42251442). Its upregulation suggests a broad alteration in transcriptional activity.
*   **NEDD8** is significantly downregulated (log2FC=-1.04, adj.p=0.0000). NEDD8 is crucial for neddylation, a post-translational modification essential for activating Cullin-RING ligases involved in ubiquitin-mediated protein degradation and cell cycle control. Its downregulation suggests impaired protein turnover or altered cellular signaling.
*   **DAD1** is significantly downregulated (log2FC=-1.02, adj.p=0000). DAD1 (Defender Against Apoptotic Death 1) is an anti-apoptotic protein, and its decrease suggests a potential shift towards increased cellular susceptibility to apoptosis.
*   **ATP6V1F** is significantly downregulated (log2FC=-1.10, adj.p=0.0000). This gene encodes a subunit of the V-type proton ATPase, critical for acidifying intracellular compartments, including lysosomes and phagosomes. Its downregulation is significant because it directly impacts the function of the enriched "Phagosome" KEGG pathway (P-value: 0.0000), suggesting impaired phagolysosomal acidification essential for antigen processing and pathogen clearance.
*   **GTF2IP4**, **AHCTF1**, **ZMIZ1**, and **NBPF10** are significantly upregulated (log2FC=1.32, 1.34, 1.14, 1.14 respectively, all adj.p=0.0000). These genes are involved in various aspects of transcriptional regulation (GTF2IP4, AHCTF1, ZMIZ1) and potentially genomic stability (NBPF10), further supporting a globally altered transcriptional landscape, possibly orchestrated by EP300.
*   **VKORC1** is significantly downregulated (log2FC=-1.18, adj.p=0.0000). VKORC1 is essential for the vitamin K cycle, crucial for the activation of blood coagulation factors. Its downregulation implies altered vitamin K metabolism.
*   **PSENEN** is significantly downregulated (log2FC=-1.01, adj.p=0000). PSENEN is a component of the gamma-secretase complex, involved in Notch signaling and amyloid precursor protein processing. Its decrease suggests potential alterations in cell development, differentiation, or neuronal function.
*   Multiple **GO Terms** related to **Antigen Processing And Presentation Of Exogenous Peptide Antigen Via MHC Class II** (GO:0019886, GO:0002495, GO:0002478) are significantly enriched (P-value: 0.0000), indicating a robust adaptive immune response.
*   The **GO Term Regulation Of Viral Genome Replication** (GO:0045069) is significantly enriched (P-value: 0.0000), suggesting an active antiviral response or ongoing viral processes.
*   The **GO Term Defense Response To Symbiont** (GO:0140546) is significantly enriched (P-value: 0.0000), providing strong evidence of an active host defense mechanism against foreign organisms.
*   **KEGG Pathways** such as **Staphylococcus aureus infection**, **Phagosome**, **Allograft rejection**, **Graft-versus-host disease**, and **Type I diabetes mellitus** are all significantly enriched (P-value: 0000), pointing towards a prominent immune activation, potentially in the context of bacterial infection, transplantation, or autoimmunity.

### Analysis:
The transcriptomic profile indicates a profound alteration in immune system activity and cellular homeostasis.
*   **Immune Activation and Pathogen Response:** The enrichment of "Antigen Processing And Presentation Of Exogenous Peptide Antigen Via MHC Class II" (GO:0019886, GO:0002495, GO:0002478) directly signifies an active adaptive immune response, where antigen-presenting cells are processing and presenting peptides, likely from pathogens or altered self-proteins, to T cells. This pathway is activated because the host system is encountering and attempting to clear a foreign entity, as strongly supported by the enrichment of "Defense Response To Symbiont" (GO:0140546) and the "Staphylococcus aureus infection" (P-value: 0.0000) KEGG pathway. The "Phagosome" (P-value: 0.0000) KEGG pathway is also highly enriched, indicating active phagocytosis. However, the downregulation of ATP6V1F (log2FC=-1.10) suggests a potential defect in the acidification of phagolysosomes, which is critical for efficient degradation and processing of antigens within the phagosome, possibly leading to less effective pathogen clearance or altered antigen presentation dynamics.
*   **Viral Regulation:** The enrichment of "Regulation Of Viral Genome Replication" (GO:0045069) suggests the cell is either under viral attack, attempting to control viral propagation, or is responding to viral components. This indicates an antiviral state or an ongoing interaction with viral elements.
*   **Alloreactivity/Autoimmunity:** The concurrent enrichment of KEGG pathways like "Allograft rejection" (P-value: 0.0000), "Graft-versus-host disease" (P-value: 0.0000), and "Type I diabetes mellitus" (P-value: 0.0000) points to a robust T-cell mediated immune response that shares molecular mechanisms with autoimmune or alloreactive conditions. These pathways are activated due to an inappropriate or excessive immune recognition, likely involving the MHC Class II presentation system (supported by GO terms), targeting self-antigens or foreign antigens in a manner typical of these diseases.
*   **Cellular Homeostasis and Gene Regulation:** The significant upregulation of EP300 (log2FC=1.19), a critical transcriptional co-activator (PMID: 42251442), along with other transcriptional regulators (GTF2IP4, AHCTF1, ZMIZ1), suggests widespread transcriptional reprogramming in response to the observed immune and pathological challenges. Conversely, the downregulation of NEDD8 (log2FC=-1.04) indicates potential defects in proteasomal degradation and cell cycle control. The downregulation of DAD1 (log2FC=-1.02) might predispose cells to increased apoptosis, while the reduction in PSENEN (log2FC=-1.01) could impact Notch signaling and other gamma-secretase-dependent processes.

### Conclusion:
The transcriptomic analysis reveals a state of intense immune activation, primarily characterized by robust MHC class II antigen presentation and processes consistent with bacterial infection (Staphylococcus aureus) and an active "Defense Response To Symbiont." Simultaneously, the molecular signature points towards an alloreactive or autoimmune-like immune response, indicated by the enrichment of pathways such as "Allograft rejection," "Graft-versus-host disease," and "Type I diabetes mellitus." Cellular homeostatic mechanisms are also perturbed, with evidence of altered protein turnover (NEDD8 downregulation), increased apoptotic susceptibility (DAD1 downregulation), and impaired phagolysosomal acidification (ATP6V1F downregulation), which could compromise effective pathogen clearance and antigen processing. The upregulation of the key transcriptional co-activator EP300 (PMID: 42251442) suggests a widespread genetic reprogramming underlying these observed changes.

**Therapeutic implications:**
*   **Immunomodulation:** Given the extensive immune activation and alloreactivity/autoimmunity signatures, targeting immune checkpoints, specific T cell subsets, or modulators of MHC Class II antigen presentation could be explored.
*   **Anti-infective strategies:** If a primary infection (e.g., bacterial as per "Staphylococcus aureus infection" or viral as per "Regulation Of Viral Genome Replication") is driving the response, appropriate anti-microbial or antiviral therapies are indicated.
*   **EP300 targeting:** Inhibitors of EP300 (log2FC=1.19, UP) could potentially dampen the pathological transcriptional reprogramming and excessive immune responses, especially if its upregulation contributes to disease pathology (PMID: 42251442).
*   **Restoring cellular function:** Therapeutic interventions aimed at restoring proper protein degradation via the neddylation pathway (NEDD8 downregulation, log2FC=-1.04) or enhancing phagolysosomal acidification (ATP6V1F downregulation, log2FC=-1.10) could improve cellular resilience and immune efficiency.
*   **Apoptosis modulation:** Strategies to counteract increased apoptotic susceptibility due to DAD1 downregulation (log2FC=-1.02) may be beneficial.

- **Confidence Assessment**: **HIGH**
- **Limitations**: *   **Lack of direct causality:** This transcriptomic analysis identifies strong associations and activated pathways, but it does not establish direct causal relationships. Functional studies are required to confirm the roles of the identified genes and pathways.
*   **Absence of contextual metadata:** The lack of information regarding the specific tissue/cell type, disease state, or experimental conditions limits a more precise clinical interpretation of the findings. For instance, the "Staphylococcus aureus infection" pathway could represent an active infection, a past exposure, or a sterile inflammatory response mimicking bacterial presence.
*   **No wet-lab validation:** The findings are derived solely from computational analysis of gene expression and require experimental validation (e.g., qPCR, Western blot, functional assays) to confirm the observed gene expression changes and their functional consequences.
*   **Limited DEG list:** Only a subset of differentially expressed genes was provided. A comprehensive list might reveal additional, nuanced pathological insights.
*   **Specificity of PMIDs:** Only PMID: 42251442 was directly applicable to a specific gene (EP300) within the provided context. The other PMIDs, while valid scientific publications, did not directly support claims about the specific DEGs or enriched pathways in this query.
